Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a rival to already-approved thera
Atara Biotherapeutics' tabelecleucel (tab-cel) has become the first 'allogeneic' cell therapy – in other words one which doesn't involve harvesting cells from patients – to be evaluated by
France's Therapixel has secured a second FDA approval for MammoScreen, its artificial intelligence-powered software for detecting cancerous lesions in mammogram images.
A web-based digital tool called Helix could help clinicians identify patients with prostate cancer who would benefit from genetic testing and counselling, according to researchers in the US
An investigator-led trial of Jazz Pharma's cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer - will get underway in the UK next year.
Share in Kura Oncology have come under pressure after a patient death in a clinical trial of the US biotech's acute myeloid leukaemia (AML) therapy KO-539, provisionally attributed to a sid